ALV-100 Clinical Trials (2026): 1 Studies for Overweight or Obese Adults & Overweight or Obese, Type 2 Diabetes
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 ALV-100 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Overweight or Obese Adults & Overweight or Obese, Type 2 Diabetes) and 180 total planned enrollment. 1 ALV-100 clinical trial is actively recruiting at 2 U.S. sites across 2 states. Most recent activity: NCT07399678 (Sep 2027).
Where to Participate: All ALV-100 Trial Sites in the U.S. (2 sites across 2 states)
Every actively recruiting ALV-100trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Clinical Pharmacology of Miami | Miami33172 | NCT07399678 | Map |
| OH | Ohio Clinical Trials | Columbus43212 | NCT07399678 | Map |
ALV-100 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting ALV-100 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07399678 | Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D | P1 | Overweight or Obese Adults | 180 | Dec 2025 |
All ALV-100 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07399678 | Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D | P1 | recruiting | 180 | Alveus Therapeutics, Inc. | Dec 2025 |
ALV-100 clinical trials: frequently asked questions
- How many ALV-100 clinical trials are there?
- 1 ALV-100 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are ALV-100 clinical trials recruiting in 2026?
- Yes — 1 ALV-100 trial is actively recruiting in 2026, with 2 U.S. sites across 2 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ALV-100 being studied for?
- ALV-100 is being studied for Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes. The trials are grouped by indication on this page.
- What phase is ALV-100 in?
- ALV-100 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ALV-100 clinical trials?
- The lead sponsor across the most ALV-100 trials is Alveus Therapeutics, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ALV-100as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: